10,000+ stock pitches from top investors available on joinyellowbrick.com
BAKER BROS. ADVISORS LP 13F Holdings
Holdings from the most recent 13F from BAKER BROS. ADVISORS LP
Filed: 2019-02-13 (Q4 2018) | Holdings: 93 | Value: $12.2B | Filing Link
PREMIUM
Author Returns
Returns are calculated from when the filing is published and are weighted by the size of the holding.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Filing Returns
Returns are calculated from when the filing is published and are weighted by the size of the holding.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Holding Returns | |||||||
|---|---|---|---|---|---|---|---|
| Stock | Put/Call | Change | Holding Pct | Value | Current Return | 3M Return | 1Y Return |
| SGEN - Seattle Genetics, Inc. | 23.68% | $2.9B | -6.46% | +72.67% | |||
| INCY - Incyte Corporation | 17.83% | $2.2B | -20.53% | -7.04% | -4.18% | ||
| BGNE - BeiGene, Ltd. | 13.74% | $1.7B | +81.79% | -1.21% | +26.65% | ||
| ALXN - Alexion Pharmaceuticals, Inc. | 6.82% | $833.0M | +2.57% | -17.77% | |||
| GHDX - Genomic Health, Inc. | Reduce 15% $(131.8M) | 6.19% | $756.4M | -29.94% | |||
| BMRN - BioMarin Pharmaceutical Inc. | 5.29% | $646.2M | -39.00% | -14.86% | -6.50% | ||
| ACAD - ACADIA Pharmaceuticals Inc. | Add 40% ($182.3M) | 5.26% | $642.2M | -2.84% | +15.32% | +107.61% | |
| AMRN - Amarin Corporation plc | Add 25% ($116.0M) | 4.75% | $579.7M | -96.62% | -2.21% | +2.68% | |
| ASND - Ascendis Pharma A/S | 1.46% | $177.8M | +133.26% | +72.30% | +101.99% | ||
| MDGL - Madrigal Pharmaceuticals, Inc. | 1.08% | $131.8M | +134.00% | -12.11% | -23.29% | ||
| HRTX - Heron Therapeutics, Inc. | 1.07% | $130.2M | -92.84% | -31.00% | -20.03% | ||
| BCRX - BioCryst Pharmaceuticals, Inc. | 1.00% | $121.9M | +20.52% | -12.11% | -68.61% | ||
| MRTX - Mirati Therapeutics, Inc. | 0.87% | $106.6M | -6.30% | +28.55% | |||
| ARGX - argenx SE | 0.80% | $97.9M | +395.60% | +4.40% | +38.49% | ||
| KNSA - Kiniksa Pharmaceuticals, Ltd. | 0.69% | $84.3M | +55.90% | -13.90% | -1.25% | ||
| RYTM - Rhythm Pharmaceuticals, Inc. | 0.60% | $72.8M | +108.25% | -12.80% | -39.32% | ||
| ARRY1 - Array BioPharma Inc. | Reduce 11% $(8.8M) | 0.59% | $71.8M | ||||
| KOD - Kodiak Sciences Inc. | New Purchase | 0.53% | $64.9M | -50.80% | +8.54% | +768.31% | |
| N/A - Neurocrine Biosciences, Inc. | New Purchase | 0.52% | $63.4M | ||||
| CERS - Cerus Corporation | 0.45% | $54.5M | -80.09% | -14.42% | -23.20% | ||
| ONCE - Spark Therapeutics, Inc. | 0.44% | $54.2M | +121.61% | ||||
| NBIX - Neurocrine Biosciences, Inc. | Reduce 23% $(15.3M) | 0.43% | $52.2M | +46.75% | -5.99% | +24.42% | |
| PRNB - Principia Biopharma Inc. | 0.40% | $49.0M | +7.37% | +122.74% | |||
| CMTA - Clementia Pharmaceuticals Inc. | Add 93% ($21.1M) | 0.36% | $43.8M | ||||
| NVTA - Invitae Corporation | Reduce 54% $(49.7M) | 0.35% | $43.2M | +19.85% | +74.23% | ||
| GWPH - GW Pharmaceuticals plc | Add 8% ($3.1M) | 0.34% | $41.7M | +17.89% | -15.27% | ||
| CBAY - CymaBay Therapeutics, Inc. | 0.32% | $38.7M | +36.35% | -82.82% | |||
| TCDA - Tricida, Inc. | 0.31% | $37.7M | +58.77% | +64.22% | |||
| DBVT - DBV Technologies S.A. | 0.29% | $35.4M | -88.94% | +19.07% | +24.90% | ||
| ZYME - Zymeworks Inc. | Add 30% ($5.8M) | 0.21% | $25.1M | -28.56% | +16.19% | +199.81% | |
| INSM - Insmed Incorporated | 0.20% | $24.3M | +169.64% | +10.44% | +18.48% | ||
| NLTX - Aquinox Pharmaceuticals, Inc. | 0.19% | $23.6M | |||||
| BOLD - Audentes Therapeutics, Inc. | Add 132% ($11.0M) | 0.16% | $19.4M | ||||
| QURE - uniQure N.V. | 0.14% | $17.4M | -61.13% | +55.79% | +69.73% | ||
| KRYS - Krystal Biotech, Inc. | New Purchase | 0.13% | $16.3M | +464.59% | +62.53% | +188.44% | |
| MRUS - Merus N.V. | 0.13% | $16.2M | +375.17% | +17.71% | +57.71% | ||
| AIMT - Aimmune Therapeutics, Inc. | 0.13% | $16.1M | -13.32% | +17.87% | |||
| XNCR - Xencor, Inc. | Reduce 27% $(5.9M) | 0.13% | $15.9M | -77.63% | -5.54% | +2.04% | |
| SLDB - Solid Biosciences Inc. | 0.13% | $15.8M | -97.40% | -23.11% | -61.44% | ||
| MYOK - MyoKardia, Inc. | Reduce 12% $(2.1M) | 0.13% | $15.4M | +15.67% | +71.79% | ||
| ABEO - Abeona Therapeutics Inc. | Reduce 4% $(579.8K) | 0.12% | $15.0M | -96.21% | +10.79% | -51.82% | |
| RARX - Ra Pharmaceuticals, Inc. | New Purchase | 0.12% | $15.0M | +18.90% | +134.69% | ||
| N/A - BioMarin Pharmaceutical Inc. | New Purchase | 0.12% | $14.9M | ||||
| IDRA - Idera Pharmaceuticals, Inc. | 0.11% | $13.4M | +2.17% | -42.39% | |||
| AGLE - Aeglea BioTherapeutics, Inc. | Add 23% ($2.4M) | 0.11% | $12.8M | -92.15% | -12.58% | +4.62% | |
| SGMO - Sangamo Therapeutics, Inc. | Reduce 22% $(3.3M) | 0.09% | $11.5M | -94.67% | +14.20% | -13.29% | |
| CFRX - ContraFect Corporation | 0.09% | $10.9M | +12.22% | +114.00% | |||
| NVAX - Novavax, Inc. | New Purchase | 0.07% | $8.7M | -83.32% | -83.80% | -82.55% | |
| MRKR - Marker Therapeutics, Inc. | New Purchase | 0.07% | $8.3M | -97.09% | +6.33% | -49.16% | |
| BLCM - Bellicum Pharmaceuticals, Inc. | 0.06% | $7.8M | -10.74% | -68.04% | |||
| N/A - BioMarin Pharmaceutical Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| N/A - BioMarin Pharmaceutical Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| N/A - Corsicanto II Designated Activity Company | Reduce 100% | 0.00% | $0.00 | ||||
| ECYT - Endocyte, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| GLPG - Galapagos NV | Reduce 100% | 0.00% | $0.00 | ||||
| N/A - Neurocrine Biosciences, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| SAGE - Sage Therapeutics, Inc. | Reduce 100% | 0.00% | $0.00 | ||||